Covid-19 roundup: Abi­vax pulls the plug on its an­ti-in­flam­ma­to­ry treat­ment; J&J says it could fall short on Q2 vac­cine sup­ply for EU — re­port

An­oth­er Covid-19 treat­ment is bit­ing the dust af­ter an in­de­pen­dent Da­ta Safe­ty and Mon­i­tor­ing Board flagged it for lack of ef­fi­ca­cy.

Paris-based Abi­vax shared last week that it’s slam­ming the brakes on its Phase IIb/III clin­i­cal tri­al for ABX464 in high-risk Covid pa­tients. The study, dubbed miR-AGE, had al­ready re­cruit­ed 500 pa­tients of the planned 1,034.

Re­searchers were test­ing the an­ti-in­flam­ma­to­ry to see if it could pre­vent se­vere dis­ease. But a planned in­ter­im analy­sis of da­ta from 306 pa­tients showed no dif­fer­ence be­tween the drug and a place­bo. ABX464 was well-tol­er­at­ed and safe, Abi­vax not­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER